Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Saved in:
| Title: | Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. |
|---|---|
| Authors: | O'Brien MP; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Forleo-Neto E; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Sarkar N; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Isa F; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Hou P; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Chan KC; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Musser BJ; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Bar KJ; Department of Medicine, University of Pennsylvania, Philadelphia.; Department of Microbiology, University of Pennsylvania, Philadelphia., Barnabas RV; Department of Global Health, University of Washington, Seattle.; Division of Allergy and Infectious Diseases, University of Washington, Seattle.; Department of Epidemiology, University of Washington, Seattle.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts., Cohen MS; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill., Hurt CB; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill., Burwen DR; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland., Marovich MA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland., Brown ER; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Biostatistics, University of Washington, Seattle., Heirman I; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Davis JD; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Turner KC; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Ramesh D; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Mahmood A; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Hooper AT; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Hamilton JD; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Kim Y; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Purcell LA; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Baum A; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Kyratsous CA; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Krainson J; Clinical Trials of Florida LLC, Miami., Perez-Perez R; Medical Research of Westchester, Miami, Florida., Mohseni R; Catalina Research Institute LLC, Montclair, California., Kowal B; Regeneron Pharmaceuticals Inc, Tarrytown, New York., DiCioccio AT; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Geba GP; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Stahl N; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Lipsich L; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Braunstein N; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Herman G; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Yancopoulos GD; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Weinreich DM; Regeneron Pharmaceuticals Inc, Tarrytown, New York. |
| Corporate Authors: | COVID-19 Phase 3 Prevention Trial Team |
| Source: | JAMA [JAMA] 2022 Feb 01; Vol. 327 (5), pp. 432-441. |
| Publication Type: | Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1538-3598 |
|---|---|
| DOI: | 10.1001/jama.2021.24939 |
